Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satraplatin with Radiation in Locally Advanced NSCLC
NCT00093132Phase 2Terminated
- Sponsor
- Agennix AG
- Start
- Aug 2004
- Primary completion
- Jan 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of satraplatin in non-small cell lung cancer (NSCLC), sponsored by Agennix AG. Primary endpoint: Maximum Tolerated Dose at 30 days. Started Aug 2004; status: terminated.
02
Drugs
satraplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00093132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093132.